GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (STU:SLZ) » Definitions » Cyclically Adjusted PB Ratio

Enveric Biosciences (STU:SLZ) Cyclically Adjusted PB Ratio : 0.00 (As of Jun. 02, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Enveric Biosciences Cyclically Adjusted PB Ratio?

As of today (2025-06-02), Enveric Biosciences's current share price is €4.6575. Enveric Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €13,534.83. Enveric Biosciences's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Enveric Biosciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Enveric Biosciences's highest Cyclically Adjusted PB Ratio was 3.00. The lowest was 0.01. And the median was 0.29.

STU:SLZ's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.475
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Enveric Biosciences's adjusted book value per share data for the three months ended in Mar. 2025 was €1.466. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €13,534.83 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Enveric Biosciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Enveric Biosciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enveric Biosciences Cyclically Adjusted PB Ratio Chart

Enveric Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.10 0.01 - -

Enveric Biosciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Enveric Biosciences's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Enveric Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enveric Biosciences's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's Cyclically Adjusted PB Ratio falls into.


;
;

Enveric Biosciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Enveric Biosciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.6575/13534.83
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enveric Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Enveric Biosciences's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.466/134.9266*134.9266
=1.466

Current CPI (Mar. 2025) = 134.9266.

Enveric Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 9,453.000 105.998 12,032.891
201903 9,874.000 107.251 12,421.996
201906 9,608.000 108.070 11,995.751
201909 12,024.000 108.329 14,976.151
201912 9,556.000 108.420 11,892.247
202003 9,248.000 108.902 11,458.072
202006 5,716.500 108.767 7,091.358
202009 5,591.500 109.815 6,870.125
202012 213.923 109.897 262.646
202103 613.577 111.754 740.802
202106 538.621 114.631 633.982
202109 1,120.524 115.734 1,306.341
202112 459.093 117.630 526.601
202203 317.043 121.301 352.656
202206 296.843 125.017 320.373
202209 165.957 125.227 178.812
202212 99.640 125.222 107.362
202303 69.921 127.348 74.082
202306 31.469 128.729 32.984
202309 15.745 129.860 16.359
202312 9.803 129.419 10.220
202403 12.270 131.776 12.563
202406 9.566 132.554 9.737
202409 5.933 133.029 6.018
202412 2.243 133.157 2.273
202503 1.466 134.927 1.466

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Enveric Biosciences  (STU:SLZ) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Enveric Biosciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Enveric Biosciences Business Description

Traded in Other Exchanges
Address
4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.